Serum and urinary cytokine levels of SLE patients

被引:35
作者
Brugos, B. [1 ]
Vincze, Z. [1 ]
Sipka, S. [1 ]
Szegedi, G. [1 ]
Zeher, M. [1 ]
机构
[1] Univ Debrecen, Dept Internal Med 3, Div Clin Immunol, H-4004 Debrecen, Hungary
来源
PHARMAZIE | 2012年 / 67卷 / 05期
关键词
SYSTEMIC-LUPUS-ERYTHEMATOSUS; BIOMARKERS; CLASSIFICATION; NEPHRITIS; MARKERS; TWEAK; CELLS;
D O I
10.1691/ph.2012.1694
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Systemic lupus erythematosus (SLE) is a chronic, relapsing, polysystemic autoimmune disease with various clinical signs. The prognosis of SLE patients is influenced by neuropsychiatric and renal involvement. Lupus nephritis (LN) is present in 40-60% of patients. Classical laboratory parameters are not sensitive and specific in prediction renal flares, over the last few years there has been a growing interest in searching novel lupus biomarkers predicting future flares. Our goal was to detect serum and urinary level of cytokines in 36 patients with lupus nephritis (34 female and 2 male, mean age: 43.36 +/- 11.53 years), 23 patients with SLE without renal involvement (19 women and 4 men, mean age: 54 +/- 8.71) (both groups followed by the 3rd Department of Internal Medicine, Division of Clinical Immunology, University of Debrecen) and 30 healthy controls (23 female and 7 male, mean age: 45.5 +/- 12.4). Serum IL-1 (interleukin), IL-2 (both p<0.05), IL-6, IL-13 and IFN-gamma (p<0.001) levels were significantly higher in lupus nephritis patients, as compared to patients with SLE without renal involvement and healthy controls. Urinary level of IL-1 and TNF-alpha were significantly higher in SLE patients without renal disease (p = 0.012 and p<0.001), while urinary IFN-gamma was significantly higher in LN patients (p=0.002). Measurement of IL-6 level in SLE patients could help to predict future renal involvement of SLE patients.
引用
收藏
页码:411 / 413
页数:3
相关论文
共 20 条
[1]  
Agrawal S, 2004, J INDIAN RHEUMATOL A, V12, P11
[2]   The role of tumor necrosis factor-alpha in systemic lupus erythematosus [J].
Aringer, Martin ;
Smolen, Josef S. .
ARTHRITIS RESEARCH & THERAPY, 2008, 10 (01)
[3]  
Cameron JS, 1999, J AM SOC NEPHROL, V10, P413
[4]   Intrarenal cytokine gene expression in lupus nephritis [J].
Chan, Rebecca Wing-Yan ;
Lai, Fernand Mac-Moune ;
Li, Edmund Kwok-Ming ;
Tam, Lai-Shan ;
Chow, Kai-Ming ;
Lai, Ka-Bik ;
Li, Philip Kam-Tao ;
Szeto, Cheuk-Chun .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (07) :886-892
[5]   Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus [J].
Chun, Hye-Young ;
Chung, Jae-Wook ;
Kim, Hyoun-Ah ;
Yun, Jeong-Moon ;
Jeon, Ja-Young ;
Ye, Young-Min ;
Kim, Seung-Hyun ;
Park, Hae-Sim ;
Suh, Chang-Hee .
JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (05) :461-466
[6]   Interleukin-6 release from peripheral mononuclear cells is associated to disease activity and treatment response in patients with lupus nephritis [J].
Esposito, Pasquale ;
Balletta, Mario M. ;
Procino, Alfredo ;
Postiglione, Loredana ;
Memoli, Bruno .
LUPUS, 2009, 18 (14) :1329-1330
[7]   Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment [J].
Fiehn, C ;
Hajjar, Y ;
Mueller, K ;
Waldherr, R ;
Ho, AD ;
Andrassy, K .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (05) :435-439
[8]   Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J].
Hochberg, MC .
ARTHRITIS AND RHEUMATISM, 1997, 40 (09) :1725-1725
[9]   Biomarkers in systemic lupus erythematosus - II. Markers of disease activity [J].
Illei, GG ;
Tackey, E ;
Lapteva, L ;
Lipsky, PE .
ARTHRITIS AND RHEUMATISM, 2004, 50 (07) :2048-2065
[10]  
Masutani K, 2001, ARTHRITIS RHEUM, V44, P2097, DOI 10.1002/1529-0131(200109)44:9<2097::AID-ART360>3.0.CO